AZD7762: The Future of Cancer Therapy? #sciencefather #AZD7762


AZD7762 is a potent checkpoint kinase 1 (Chk1) inhibitor designed to enhance the efficacy of DNA-damaging therapies like chemotherapy and radiation by disrupting cancer cells' ability to repair DNA. By inhibiting Chk1, AZD7762 abrogates the G2/M cell cycle checkpoint, leading to increased DNA damage, mitotic catastrophe, and apoptosis in tumor cells. Preclinical studies have demonstrated its potential in sensitizing various cancers—including triple-negative breast cancer, urothelial carcinoma, osteosarcoma, and pancreatic cancer—to agents like gemcitabine, cisplatin, and radiation . Visit Our Website : http://biotechnologyscientist.com Contact Us : support@biotechnologyscientist.com Nomination Link : https://biotechnologyscientist.com/award-nomination/?ecategory=Awards&rcategory=Awardee #AZD7762 #Chk1Inhibitor #CancerTherapy #DNARepair #MitoticCatastrophe #TripleNegativeBreastCancer #UrothelialCarcinoma #Osteosarcoma #PancreaticCancer #Gemcitabine #Cisplatin #RadiationTherapy #CellCycleCheckpoint #Apoptosis #Cardiotoxicity #BAG3 #TargetedTherapy #OncologyResearch #PrecisionMedicine #ClinicalTrials

Comments

Popular posts from this blog

HIV: Mechanisms, Types, and Advances in Treatment #sciencefather #researchawards #HIV #AIDS #Retrovirus #ImmuneSystem #CD4Cells

Premier Biotechnology Award

"Genes and Beyond: Unraveling the Mysteries of Heredity" #sciencefather#researchawards#Scientist#Genomics #GeneticResearch #MolecularBiology #GeneTherapy